Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Lymphoid 2Genitourinary 2Breast 2Thoracic 1Plasma cell 1Myeloid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Urologic Neoplasms 1Thyroid Neoplasms 1Soft Tissue Neoplasms 1Sarcoma 1Recurrence 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Lymphangioleiomyomatosis 1Erdheim-Chester Disease 1Endocrine Gland Neoplasms 1Castleman Disease 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

Cisplatin 30pembrolizumab 24Magnetic Resonance Spectroscopy 24Specimen Handling 20Cetuximab 18Nivolumab 15Carboplatin 14Platinum 121,2-diaminocyclohexaneplatinum II citrate 12Radiotherapy, Intensity-Modulated 11Radiotherapy 10Radiation 9Paclitaxel 9Docetaxel 8Biopsy 8Immunoglobulin G 7Disulfides 7Surveys and Questionnaires 6Ipilimumab 6atezolizumab 5Fluorouracil 5toripalimab 4dostarlimab 4cemiplimab 4cabozantinib 4Taxes 4Gemcitabine 4CTLA-4 Antigen 4Bevacizumab 4(225)Ac-DOTA-c(RGDyK) 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
temsirolimus × Head & Neck × 30 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡